Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Thomas Chen

Tracked across 1 events · 7 articles · First seen Aug 26, 2026 · Last active Aug 28, 2026

Sentiment
50
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 50
Business
Neonci Technologies reported positive topline results from its NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint with 48.9% six-month progression-free…
Impact: Director Thomas Chen's share purchases also indicate insider confidence in NeOnc's prospects.
Aug 26, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Thomas Chen live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.